Tibet Rhodiola Pharmaceutical Holding

Tibet Rhodiola Pharmaceutical Holding EBITDA per Share

The EBITDA per Share of Tibet Rhodiola Pharmaceutical Holding (600211.SS) as of Oct 31, 2026 is 2.87 CNY. In the previous year, EBITDA per Share was 3.69 CNY — a change of -22.20% (lower).

EBITDA per Share

2.87CNY

YoY

-22.20%

Last updated:

EBITDA per Share of Tibet Rhodiola Pharmaceutical Holding is 2025 2.87 CNY. EBITDA per Share of Tibet Rhodiola Pharmaceutical Holding was 2024 3.69 CNY. It decreases by -22.20% lower compared to the previous year.

The Tibet Rhodiola Pharmaceutical Holding EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
0.76 CNY
Jan 1, 2019
1.08 CNY
Jan 1, 2020
1.08 CNY
Jan 1, 2021
0.83 CNY
Jan 1, 2022
1.52 CNY
Jan 1, 2023
2.86 CNY
Jan 1, 2024
3.69 CNY
Jan 1, 2025
2.87 CNY
The Tibet Rhodiola Pharmaceutical Holding EBITDA per Share history
YEAREBITDA per ShareYoY
2.87CNY-22.20%
3.69CNY+28.95%
2.86CNY+88.34%
1.52CNY+83.32%
0.83CNY-23.35%
1.08CNY+0.32%
1.08CNY+42.06%
0.76CNY+14.03%
0.66CNY-12.57%
0.76CNY+74.71%
0.44CNY+249.48%
0.12CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Rhodiola Pharmaceutical Holding Stock analysis

What does Tibet Rhodiola Pharmaceutical Holding do? Tibet Rhodiola Pharmaceutical Holding Co. generates revenue through the manufacture and wholesale of pharmaceutical products. The company distributes proprietary drug products and processes pharmaceuticals, serving markets across South China, North China, East China, Central China, and overseas regions. Its primary customers are pharmaceutical distributors and healthcare providers within these regions, focusing on the distribution of its proprietary drug portfolio. The firm's revenue streams are derived from the wholesale of manufactured pharmaceuticals and the processing of pharmaceutical products. It operates through a network of distributors in key Chinese regions and overseas markets, targeting healthcare institutions and pharmacies that require its proprietary drug solutions. The company's business model emphasizes regional distribution networks to reach its target segments efficiently. Tibet Rhodiola Pharmaceutical Holding Co. relies on its proprietary drug products for sales, with a strong presence in multiple Chinese regions and overseas markets. The company's revenue is driven by the distribution of these products through its established wholesale channels, catering to the healthcare sector's demand for pharmaceutical solutions in its operational areas. Tibet Rhodiola Pharmaceutical Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Rhodiola Pharmaceutical Holding stock

EBITDA per Share of Tibet Rhodiola Pharmaceutical Holding is 2.87 CNY in 2025.

EBITDA per Share of Tibet Rhodiola Pharmaceutical Holding changed from 3.69 CNY to 2.87 CNY, representing a -22.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Tibet Rhodiola Pharmaceutical Holding since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Tibet Rhodiola Pharmaceutical Holding

All Key Metrics — Tibet Rhodiola Pharmaceutical Holding